Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK Plc

GSK Plc reaches US agreement to reduce prescription medicine costs

GSK has entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients, including treatments across its respiratory portfolio for asthma and COPD...
EDX Medical Group plc

EDX Medical reports interim progress with revenue growth expected from diagnostics pipeline

EDX Medical Group has released its interim results for the six months to 20 September 2025, reporting continued progress across its diagnostics portfolio...
EDX Medical

EDX Medical launches BC95 bowel cancer testing service in the UK

EDX Medical Group has announced the UK launch of its BC95 bowel cancer testing service, designed to improve early detection and assess hereditary risk...
GSK

GSK secures FDA approval for Exdensur in severe eosinophilic asthma

GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and over...
Aptamer Group

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products...
AstraZeneca

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer...
GSK plc

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients...
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals CEO Riad Mishlawi steps down, Executive Chairman assumes role

Hikma Pharmaceuticals has announced that Riad Mishlawi has stepped down as Chief Executive Officer and as a board member by mutual agreement...
GSK plc

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026...
Ethtry plc

Ethtry adds two new Advisory Board members

Ethtry has added Mike Foy and Marc Degen to its new Advisory Board, bringing experience across digital assets, fintech and Web3 ventures...
GSK

GSK receives US FDA Orphan Drug Designation for SCLC treatment risvutatug rezetecan

GSK has announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has been granted Orphan Drug Designation by the US FDA for small-cell lung cancer...

Oxford Nanopore names Francis Van Parys as new CEO from March 2026

Oxford Nanopore Technologies has appointed Francis Van Parys as Chief Executive Officer, effective 2 March 2026...
Smith & Nephew plc

Smith & Nephew outlines RISE strategy with upgraded guidance and new 2028 financial targets

Smith & Nephew has introduced its RISE strategy at its Capital Markets Day, setting out 2028 targets for stronger revenue growth, higher profit and increased free cash flow...
Ethtry plc

Ethtry appoints John Robinson as Company Secretary

Ethtry has appointed John Robinson as Company Secretary, bringing over 28 years of audit, assurance and M&A experience across international markets including Europe, Africa and emerging technology sectors...
Halma plc

Halma Plc acquires E2S Group for £230m to expand industrial safety capabilities

Halma has acquired E2S Group for £230m, adding a manufacturer of notification and detection devices used in hazardous industrial settings...
Ethtry plc

Ethtry Plc closes £5.3m fundraise, CEO subscribes

Ethtry PLC has received a further £86,000 in subscription monies, bringing the total raised to £5.302m and confirming the Fundraise is now closed...
Faron Pharmaceuticals

Faron Pharmaceuticals appoints new CFO Jurriaan Dekkers

Faron Pharmaceuticals has named Jurriaan Dekkers as its new Chief Financial Officer from 1 December 2025...
Aptamer Group

Aptamer Group AGM statement highlights contract wins and growing order book

Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million...
intravenous (IV) line

AstraZeneca wins US approval for Imfinzi in early gastric and GEJ cancers

AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers...
AstraZeneca

AstraZeneca Plc to invest $2 billion in major Maryland manufacturing expansion

AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in Frederick and a new clinical manufacturing site in Gaithersburg...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

H

GSK Plc

GSK Plc reaches US agreement to reduce prescription medicine costs

GSK has entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients, including treatments across its respiratory portfolio for asthma and COPD...
EDX Medical Group plc

EDX Medical reports interim progress with revenue growth expected from diagnostics pipeline

EDX Medical Group has released its interim results for the six months to 20 September 2025, reporting continued progress across its diagnostics portfolio...
EDX Medical

EDX Medical launches BC95 bowel cancer testing service in the UK

EDX Medical Group has announced the UK launch of its BC95 bowel cancer testing service, designed to improve early detection and assess hereditary risk...
GSK

GSK secures FDA approval for Exdensur in severe eosinophilic asthma

GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and over...
Aptamer Group

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products...
AstraZeneca

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer...
GSK plc

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients...
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals CEO Riad Mishlawi steps down, Executive Chairman assumes role

Hikma Pharmaceuticals has announced that Riad Mishlawi has stepped down as Chief Executive Officer and as a board member by mutual agreement...
GSK plc

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026...
Ethtry plc

Ethtry adds two new Advisory Board members

Ethtry has added Mike Foy and Marc Degen to its new Advisory Board, bringing experience across digital assets, fintech and Web3 ventures...
GSK

GSK receives US FDA Orphan Drug Designation for SCLC treatment risvutatug rezetecan

GSK has announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has been granted Orphan Drug Designation by the US FDA for small-cell lung cancer...

Oxford Nanopore names Francis Van Parys as new CEO from March 2026

Oxford Nanopore Technologies has appointed Francis Van Parys as Chief Executive Officer, effective 2 March 2026...
Smith & Nephew plc

Smith & Nephew outlines RISE strategy with upgraded guidance and new 2028 financial targets

Smith & Nephew has introduced its RISE strategy at its Capital Markets Day, setting out 2028 targets for stronger revenue growth, higher profit and increased free cash flow...
Ethtry plc

Ethtry appoints John Robinson as Company Secretary

Ethtry has appointed John Robinson as Company Secretary, bringing over 28 years of audit, assurance and M&A experience across international markets including Europe, Africa and emerging technology sectors...
Halma plc

Halma Plc acquires E2S Group for £230m to expand industrial safety capabilities

Halma has acquired E2S Group for £230m, adding a manufacturer of notification and detection devices used in hazardous industrial settings...
Ethtry plc

Ethtry Plc closes £5.3m fundraise, CEO subscribes

Ethtry PLC has received a further £86,000 in subscription monies, bringing the total raised to £5.302m and confirming the Fundraise is now closed...
Faron Pharmaceuticals

Faron Pharmaceuticals appoints new CFO Jurriaan Dekkers

Faron Pharmaceuticals has named Jurriaan Dekkers as its new Chief Financial Officer from 1 December 2025...
Aptamer Group

Aptamer Group AGM statement highlights contract wins and growing order book

Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million...
intravenous (IV) line

AstraZeneca wins US approval for Imfinzi in early gastric and GEJ cancers

AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers...
AstraZeneca

AstraZeneca Plc to invest $2 billion in major Maryland manufacturing expansion

AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in Frederick and a new clinical manufacturing site in Gaithersburg...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple